In this study, we conducted REST gene editing and PROX1 transgene analysis and attempted to utilize the transgene pro-opiomelanocortin (POMC) as an intragranular molecule to define suitable conditions for producing ESGs using the undifferentiated non-neuroendocrine cancer cell line H1299. This evidence concerns the gene POMC and neuroendocrine carcinoma.